Crohn’s disease is a chronic inflammatory bowel disease, involving gastrointestinal tract and extra-intestinal organs. IgA nephropathy is a rare extra-intestinal manifestation of Crohn’s disease. We describe a case of 21-year old Korean man who was diagnosed with Crohn’s disease 5 years after IgA nephropathy was suspected. At the age of 16, he had gross hematuria and 2 years after he was diagnosed with IgA nephropathy. Three years later, he complained of abdominal pain and diarrhea. He was diagnosed with Crohn’s disease by colonoscopy and histologic exams. There has been increasing evidences of common pathophysiology between the two diseases.

Background: Traditional plant drugs, are less toxic and free from side effects compared to general synthetic drugs. They have been used for the treatment of diabetes and associated renal damage. In this study, we evaluated effect of Hachimi-jio-gan against diabetic renal damage in a rat model of type 1 diabetic nephropathy induced by subtotal nephrectomy plus streptozotocin (STZ) injection, and in Otsuka Long-Evans Tokushima Fatty (OLETF) rats and db/db mice as a model of human type 2 diabetes, and its associated complications. To explore the active components of Hachimi-jio-gan, the antidiabetic effect of corni fructus, a consituent of Hachimi-jio-gan, and 7-O-galloyl-D-sedoheptulose, a phenolic compound isolated from corni fructus, were investigated. Methods and Results: We conducted an extensive literature search, and all required data were collected and systematically organized. The findings were reviewed and categorized based on relevance to the topic. A summary of all the therapeutic effects were reported as figures and tables. Conclusions: Hachimi-jio-gan serves as a potential therapeutic agent to against the development of type 1 and type 2 diabetic nephropathy. From the results of characterization active components of corni fructus, 7-O-galloyl-D-sedoheptulose is considered to play an important role in preventing and/or delaying the onset of diabetic renal damage. 7-O-Galloyl-D-sedoheptulose is expected to serve as a novel therapeutic agent against the development of diabetic nephropathy.

There are many known renal complications of rheumatoid arthritis. These complications can develop by the extraarticular aspect of rheumatoid arthritis or the use of disease modifying antirheumatic drugs or pain-killer. The most common renal disease induced by use of disease modifying antirheumatic drugs is membranous nephropathy. We report on a case of bucillamine induced nephropathy with prominent proteinuria and hypoalbuminemia. The renal biopsy result was stage I to II membranous nephropathy. After withdrawal of bucillamine the proteinuria improved and hypoalbuminemia recovered. Even in cases of accompanying prominent proteinuria and hypoalbuminemia, bucillamine nephropathy can be treated with withdrawal of bucillamine and immunosuppressant drugs are not required.